Efficacy of Notrande Shuhuajun Probiotic Supplement on Lmproving Constipation in Preschool Children
NCT ID: NCT07002489
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
102 participants
INTERVENTIONAL
2025-05-30
2025-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Does Notrande Shuhuajun Probiotic Supplement intake improve functional constipation in preschool children?
105 eligible participants will be enrolled in one center and assigned the study product. After one week washout period participants need to take in the product for two weeks, followed by a one-week regression period.
Researchers will collect data, analyze data and conclude whether the study product is effective to improve constipation in participants, by comparing the change of concentration of biochemical indicators SCFA (Short-chain fatty acids), Lactobacillus and Bifidobacterium, and visual analysis of Bristol Stool scale etc..
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Notrande Shuhuajun Probiotic Supplement Study Product
Notrande Shuhuajun Probiotic Supplement, Each capsule contains the following active ingredients: ≥79.5 mg of the specially developed formula, 1 × 108 CFU of Lactobacillus fermentum CECT5716, 5 × 109 CFU of Lactobacillus rhamnosus GG, 5 × 109 CFU of Bifidobacterium animalis (Lactobacillus subspecies HNO19), and 1 × 108 CFU of Lactobacillus rhamnosus HNO01.
Nuotelande Shuhuajun Study Product
Participants in this arm need to take in the assigned product - Notrande Shuhuajun Probiotic Supplement, 1 capsule per day, for 14 consecutive days. Don't take in similar products in the following 7 days (regression phase).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nuotelande Shuhuajun Study Product
Participants in this arm need to take in the assigned product - Notrande Shuhuajun Probiotic Supplement, 1 capsule per day, for 14 consecutive days. Don't take in similar products in the following 7 days (regression phase).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants were diagnosed with functional constipation based on Rome IV criteria;
* Participants agreed not to take any drugs, supplements, or other dairy products during the trial period;
* Participants agreed not to take any other prebiotic/bacterial drugs, supplements, or dairy products including yogurt beverages during the trial period;
* Be willing to refrain from participating in other interventional clinical studies during the trial period;
* Be able to fully understand the nature, purpose, benefits obtained, as well as possible risks and side effects of this study;
* Be willing to comply with all test requirements and procedures;
* Sign the informed consent form;
Exclusion Criteria
* Lactose intolerance;
* Currently suffering from other organic diseases that affect intestinal function, such as a history of gastrointestinal resection, colon or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, congenital megacolon, scleroderma, anorexia nervosa, etc;
* Have been controlling diet, increasing exercise, or taking drugs to control weight or affect appetite in the last three months;
* Have any of the following medical histories or have been clinically diagnosed with any of the following diseases that may affect the evaluation of the trial effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases;
* Current or past abuse of alcohol or other prohibited drugs, supplements or OTC prescription drugs may cause intestinal dysfunction or affect the evaluation of the test results;
* According to the researchers' judgment, drugs that may affect gastrointestinal function or the immune system are currently being frequently used;
* Laxatives or other digestive AIDS were used two weeks before the start of the trial;
* Have consumed dairy products or other foods containing prebiotics/bacteria 10 days before the start of the trial;
* The research doctors believed that the volunteers could not fully cooperate with the trial arrangements;
3 Years
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong Sibote Biotechnology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charlie Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Raison Biotech Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuyang Fifth People's Hospital Quanying Branch
Fuyang, Anhui, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-RD-04-JJ-001
Identifier Type: -
Identifier Source: org_study_id